FDA Approves New CPR System to Improve Cardiac Arrest Survival
The Food and Drug Administration (FDA) has approved the ResQCPR System (Advance Circulatory Systems, Inc.), which is comprised of two devices for first responders to use while performing cardiopulmonary resuscitation (CPR) on individuals during cardiac arrest to help improve the patient's chance of survival.
The two devices in the ResQCPR System are intended to be used in conjunction to assist in performing CPR on adult patients with out-of-hospital, non-traumatic cardiac arrest. The ResQPump Active Compression Decompression CPR Device has a double-grip handle that attaches to the patient's chest with a suction cup to allow the rescuer to push to deliver compressions and a lift for decompressions. Also included is a pressure gauge to assist rescuers in maintaining recommended compression depth and a timing mechanism for maintaining the necessary compression rate. The ResQPod 16.0 Impedance Threshold Device fits onto a rescue face mask or breathing tube to impede airflow into the chest during chest decompression, reducing the pressure inside the patient's chest, and drawing more blood back into the heart (preloading). The devices may increase the amount of oxygenated blood circulating through a patient's body during CPR when used in conjunction.
The approval was based on an FDA data review, including a randomized clinical trial that compared survival rates of 813 subjects receiving standard CPR to 842 subjects who received CPR with the ResQCPR System. A larger number of subjects who received CPR with the System survived cardiac arrest compared to those receiving standard CPR.
For more information visit FDA.gov.